Adverum Competitors
| ADVM Stock | USD 6.64 0.19 2.95% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Adverum Biotechnologies competition on your existing holdings.
Adverum |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Adverum Biotechnologies' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Adverum Biotechnologies Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Adverum Biotechnologies and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Adverum and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Adverum Biotechnologies does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Adverum Stock performing well and Adverum Biotechnologies Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Adverum Biotechnologies' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| QURE | 3.97 | (0.42) | 0.00 | 0.03 | 4.54 | 11.07 | 36.04 | |||
| RCKT | 2.82 | (0.56) | 0.00 | (0.17) | 0.00 | 6.59 | 21.07 | |||
| RYTM | 2.31 | 0.24 | 0.13 | 0.25 | 2.34 | 6.15 | 17.61 | |||
| SLDB | 3.47 | (0.89) | 0.00 | (0.21) | 0.00 | 7.44 | 24.49 | |||
| MGTX | 2.72 | 0.58 | 0.22 | 0.43 | 2.52 | 6.75 | 21.07 | |||
| AVTE | 2.44 | 0.45 | 0.18 | 0.60 | 2.04 | 5.58 | 19.11 | |||
| ADAG | 4.38 | (0.15) | 0.00 | (0.54) | 0.00 | 8.13 | 37.93 | |||
| ACRV | 2.87 | (0.45) | 0.00 | (0.13) | 0.00 | 7.66 | 22.84 | |||
| RZLT | 2.76 | 0.01 | 0.02 | 0.13 | 3.12 | 6.80 | 30.01 | |||
| ANTX | 2.25 | 0.55 | 0.19 | 0.70 | 1.69 | 6.00 | 28.03 |
Cross Equities Net Income Analysis
Compare Adverum Biotechnologies and related stocks such as Uniqure NV, Rocket Pharmaceuticals, and Rhythm Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| QURE | (22.4 M) | (22.4 M) | (19.5 M) | (37 M) | (45 M) | (78.1 M) | (73.4 M) | (80.4 M) | (83.3 M) | (128 M) | (125 M) | 329.6 M | (126.8 M) | (308.5 M) | (293.1 M) |
| RCKT | (6.1 M) | (6.1 M) | (6.1 M) | (7.6 M) | (9.5 M) | (68 M) | (42.9 M) | (29.5 M) | (74.5 M) | (83.2 M) | (146.7 M) | (169.6 M) | (219.4 M) | (245.6 M) | (233.3 M) |
| RYTM | (18.1 M) | (18.1 M) | (18.1 M) | (21.4 M) | (6.5 M) | (11.1 M) | (25.9 M) | (33.7 M) | (74.1 M) | (134.6 M) | (130.7 M) | (68 M) | (183.1 M) | (184.7 M) | (175.4 M) |
| SLDB | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (6.4 M) | (21.5 M) | (52.1 M) | (74.8 M) | (115.6 M) | (90.1 M) | (72.1 M) | (65.5 M) | (96 M) | (100.8 M) |
| MGTX | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (19.5 M) | (31 M) | (82.9 M) | (52.6 M) | (54 M) | (72 M) | (142.9 M) | (84 M) | (88.2 M) |
| AVTE | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (9 M) | (23 M) | (51.5 M) | (75.5 M) | (71.7 M) |
| ADAG | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (17.3 M) | (16.4 M) | (73.2 M) | (80 M) | (18.9 M) | (19.9 M) |
| ACRV | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (5.3 M) | (16.2 M) | (29.7 M) | (60.4 M) | (57.4 M) |
| RZLT | (49.3 K) | (49.3 K) | (6.7 M) | (9.7 M) | (11.4 M) | (14.9 M) | (20.3 M) | (29.9 M) | (30.4 M) | (20.3 M) | (21.3 M) | (38.8 M) | (51.8 M) | (68.5 M) | (65 M) |
| ANTX | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (13.6 M) | (21.5 M) | (41.5 M) | (64.7 M) | (61.5 M) |
| PASG | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (54.6 M) | (111.8 M) | (191.5 M) | (136.9 M) | (102.1 M) | (107.2 M) |
| ABSI | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (14.6 M) | (101 M) | (104.9 M) | (110.6 M) | (105 M) |
| KZR | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (9 M) | (8.5 M) | (23.2 M) | (31.5 M) | (39 M) | (53.3 M) | (65.3 M) | (101.9 M) | (96.8 M) |
| ONCT | (750 K) | (33.3 M) | (27.1 M) | (42.1 M) | (39.4 M) | (18.7 M) | (17.7 M) | (30.4 M) | (38.4 M) | (15.9 M) | (17.2 M) | (31.3 M) | (43.4 M) | (39.5 M) | (41.5 M) |
| KOD | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (27.9 M) | (41.4 M) | (46.7 M) | (133.1 M) | (267 M) | (333.8 M) | (260.5 M) | (247.5 M) |
| GLMD | (3.1 M) | (3.1 M) | (3.1 M) | (17.5 M) | (9.1 M) | (10.6 M) | (17 M) | (12.3 M) | (9.9 M) | (18.5 M) | (27.6 M) | (31.9 M) | (18.6 M) | (6.9 M) | (7.3 M) |
| AFMD | (14.3 M) | (14.3 M) | (14.3 M) | (26.1 M) | (259 K) | (20.2 M) | (32.2 M) | (30.2 M) | (19.5 M) | (32.4 M) | (41.4 M) | (57.5 M) | (86 M) | (105.9 M) | (100.6 M) |
| MREO | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (28.4 M) | (38.8 M) | (32 M) | (34.8 M) | (163.6 M) | 12.7 M | (34.2 M) | (29.5 M) | (30.9 M) |
| STOK | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (12.5 M) | (28.5 M) | (50.6 M) | (84.7 M) | (93.1 M) | (104.7 M) | (99.5 M) |
Adverum Biotechnologies and related stocks such as Uniqure NV, Rocket Pharmaceuticals, and Rhythm Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Adverum Biotechnologies financial statement analysis. It represents the amount of money remaining after all of Adverum Biotechnologies operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Adverum Biotechnologies Competitive Analysis
The better you understand Adverum Biotechnologies competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Adverum Biotechnologies' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Adverum Biotechnologies' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Adverum Biotechnologies Competition Performance Charts
Five steps to successful analysis of Adverum Biotechnologies Competition
Adverum Biotechnologies' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Adverum Biotechnologies in relation to its competition. Adverum Biotechnologies' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Adverum Biotechnologies in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Adverum Biotechnologies' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Adverum Biotechnologies, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Adverum Biotechnologies position
In addition to having Adverum Biotechnologies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Energy Funds Thematic Idea Now
Energy Funds
Funds or Etfs investing in energy sector, natural resources, and ecology. The Energy Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Adverum Biotechnologies Correlation with its peers. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share 0.059 | Quarterly Revenue Growth (0.70) | Return On Assets (0.30) | Return On Equity (0.76) |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.